Institute for Gynecological Oncology

The Institute for Gynecological Oncology (SPGO), based in Mannheim, Germany, is a specialized clinical research institute and medical practice focused on the treatment and study of gynecological malignancies and breast cancer. Led by Professor Ingo J. Diel, the institute is a prominent international site for Phase 2 and Phase 3 clinical trials, collaborating extensively with major pharmaceutical companies such as Amgen and Novartis. It played a significant role in the clinical development and regulatory approval of therapies like Xgeva (denosumab) for bone metastases. The institute provides advanced oncological care while contributing to global research in supportive care and targeted therapies for women's cancers.